SCHEMBL1471691

SCHEMBL1471691

O=C1C=C(c2ccc(O)cc2)C(=O)N1c1cccc(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.49
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
ALDH1A1 P00352 4/20 0.43
MAPT P10636 4/20 0.43
LMNA P02545 2/20 0.43
APOBEC3G Q9HC16 1/20 0.43
MAPK1 P28482 1/20 0.42
PRKCZ Q05513 2/20 0.41
NR1H3 Q13133 1/20 0.41
NOX4 Q9NPH5 1/20 0.40
NOX1 Q9Y5S8 1/20 0.40
ESR1 P03372 1/20 0.40
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CASP6 P55212 1/20 0.39
HCRTR1 O43613 1/20 0.39
S1PR4 O95977 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471117 0.90 MGLL (0.53) MGLLMEN1KMT2AALDH1A1MAPT
SCHEMBL1471296 0.87 MGLL (0.50) MGLLMEN1KMT2AALDH1A1MAPT
SCHEMBL934144 0.87 MGLL (0.53) MGLLMEN1KMT2AALDH1A1MAPT
SCHEMBL1471795 0.86 ALOX5 (0.50) MGLLMEN1KMT2AALDH1A1MAPT
SCHEMBL1471051 0.86 MAPT (0.49) MGLLMEN1KMT2AALDH1A1MAPT
SCHEMBL1471819 0.86 MGLL (0.49) MGLLMEN1KMT2AALDH1A1MAPT
SCHEMBL1471844 0.83 MGLL (0.43) MGLLMEN1KMT2AALDH1A1MAPT
SCHEMBL1471712 0.82 MAPT (0.62) MGLLMEN1KMT2AALDH1A1MAPT
SCHEMBL1473707 0.82 MGLL (0.47) MGLLMEN1KMT2AALDH1A1MAPT
SCHEMBL1471316 0.81 HSP90AA1 (0.39) MGLLKMT2AMAPK1PRKCZESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915304-B2 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT CONGENIA S.R.L. (IT) 2011-03-29 US claimed
EP-2091531-B1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S R L (IT) 2010-11-24 EP claimed
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2010-04-22 US claimed
EP-2091531-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT Congenia S.r.l. (IT) 2009-08-26 EP claimed
WO-2008067863-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2008-06-12 WO claimed
WO-2016144352-A2 THERAPEUTIC COMPOSITIONS INCLUDING ACRYLAMIDO COMPOUNDS OR PHENYL-SUBSTITUTED MALEIMIDE COMPOUNDS, VARIANTS THEREOF AND METHODS OF USING THE SAME STEALTH PEPTIDES INTERNATIONAL, INC. (MC) 2016-09-15 WO disclosed
US-7915304-B2 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT CONGENIA S.R.L. (IT) 2011-03-29 US disclosed
EP-2091531-B1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S R L (IT) 2010-11-24 EP disclosed
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2010-04-22 US disclosed
EP-2091531-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT Congenia S.r.l. (IT) 2009-08-26 EP disclosed
WO-2008067863-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CYC1, MTPN, TXN2 MGLL 857/4885MEN1 1535/4885KMT2A 4798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.